Monika Graeser

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (50)

• Data from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.c.8232103
  +Save
• Value of Axillary Palpation and Ultrasound, and Axillary Recurrence in Male Breast Cancer: Results of the Registry Study
  International Journal of Cancer 2026 DOI: 10.1002/ijc.70658
  +Save
• Supplementary Table 3 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006915
  +Save
• Supplementary Table 2 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006918
  +Save
• Supplementary Table 1 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006921
  +Save
• Supplementary Figure 6 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006924
  +Save
• Supplementary Figure 5 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006927
  +Save
• Supplementary Figure 4 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006930
  +Save
• Supplementary Figure 3 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006933
  +Save
• Supplementary Figure 2 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
  2026 DOI: 10.1158/1078-0432.31006936
  +Save